Market Place
Sourcing Support
Cytomed Bids Cash For TC Biopharma Assets Acquisition
14 Oct 2025 //
GLOBENEWSWIRE
TCBP Announces Transition from Nasdaq to OTC Markets
21 Mar 2025 //
PR NEWSWIRE
TCBP CEO Bryan Kobel Joins Cancer Progress Panel At European Forum
20 Feb 2025 //
PR NEWSWIRE
TCBP Completes Cohort A In ACHIEVE Clinical Trial
13 Feb 2025 //
PR NEWSWIRE
TCBP Completes Initial Cohort B Dosing In ACHIEVE Trial
10 Feb 2025 //
PR NEWSWIRE
TCBP to Implement ADS Ratio Change
05 Feb 2025 //
PR NEWSWIRE
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
06 Jan 2025 //
PR NEWSWIRE
TCBP Partners With CareDx To Aid Cell Therapy Pharmacokinetic Study
11 Dec 2024 //
PR NEWSWIRE
TCBP Announces Dosing of 5 New Patients in ACHIEVE
03 Sep 2024 //
PR NEWSWIRE
TC BioPharm Announces Closing of $2.0 Million Public Offering
15 Aug 2024 //
PR NEWSWIRE
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering
13 Aug 2024 //
PR NEWSWIRE
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on `The Big Biz Show`
29 Jan 2024 //
PR NEWSWIRE
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement
04 Jan 2024 //
PR NEWSWIRE
TC BioPharm Announces Additional Cost Reduction Steps
03 Jan 2024 //
PR NEWSWIRE
TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico
19 Apr 2023 //
GLOBENEWSWIRE
TC Bio Receives Notice of Non-compliance with NASDAQ`s Listing Rule 5550(b)(1)
19 Jan 2023 //
PR NEWSWIRE
TC BioPharm Announces Closing of $7.35 Million Private Placement
30 Nov 2022 //
PRESS RELEASE
TC BioPharm Announces $7.35 Million Private Placement
28 Nov 2022 //
PRESS RELEASE
TC BioPharm doses first subjects in Phase IIb leukaemia trial
23 Nov 2022 //
CLINICALTRIALSARENA
TC BioPharm Begins Dosing Phase 2B Study Evaluating Lead Compound, OmnImmune
22 Nov 2022 //
PRESS RELEASE
TC BioPharm to Present at Upcoming Investor Conferences
03 Oct 2022 //
PRNEWSWIRE
TC BioPharm Executives to Speak at The 3rd Gamma Delta T Therapies Summit
25 Jul 2022 //
PRNEWSWIRE
TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering
02 Jun 2022 //
PRNEWSWIRE
Kuick Research Recognizes TC BioPharm in Gamma-Delta T Cell Market
23 May 2022 //
PRNEWSWIRE
TC BioPharm Announces Formation of Scientific Advisory Board
18 May 2022 //
PRNEWSWIRE
TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship
21 Apr 2022 //
PRNEWSWIRE
TC Biopharm Updates Intellectual Property Portfolio
15 Mar 2022 //
PRESS RELEASE
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage AML
08 Mar 2022 //
PRESS RELEASE
TC Biopharm Announces Closing of $17.5 Million Initial Public Offering
15 Feb 2022 //
PRNEWSWIRE
TC BioPharm Announces Launch of COVID-19 Phase I/II Human Trial
13 Oct 2021 //
PRNEWSWIRE
TC BioPharm Named as Top 5 Female Powered Companies in United Kingdom
12 Aug 2021 //
BUSINESSWIRE
TC BioPharm Initiates Ph I Trial of Allogeneic Gamma Delta T Cell Therapy
24 Apr 2019 //
BUSINESSWIRE
TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy product
22 Jan 2019 //
BUSINESSWIRE
Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm
07 Dec 2017 //
ENDPTS
